ASTH Financials Astrana Health, Inc.

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Aug 16, 2026, 10:12 UTC Overview →

Growth & profitability

Revenue has grown 35.9% per year over the past 5 years.
Net income has grown slower than revenue (-8.6% vs 35.9% per year).
Operating margin has contracted, at 2.5% in the latest year.
Free cash flow has grown 18.4% per year over the past 5 years.

Financial health

Total debt ($1.0B) exceeds cash ($429M); net debt is $609M.
Total debt has grown in line with revenue (33.9% vs 35.9% per year).
Operating income covered interest expense 1.6× in the latest year.
Total debt is 8.4× EBITDA.

Shareholder returns

Dividends have been paid for 8 consecutive years, consuming 32.9% of earnings and 7.5% of free cash flow.
The dividend has declined 31.2% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
2025	$3.2B	$24M	0.0%	2.5%	3.1%	1.1%	$104M	$1.0B	$429M
2024	$2.0B	$50M	0.0%	4.4%	7.0%	3.7%	$44M	$435M	$288M
2023	$1.4B	$58M	0.0%	6.1%	9.4%	6.2%	$40M	$278M	$294M
2022	$1.1B	$46M	0.0%	9.1%	8.5%	4.8%	$59M	$204M	$288M
2021	$774M	$46M	23.0%	12.7%	10.3%	5.3%	$51M	$184M	$233M
2020	$687M	$38M	21.5%	11.7%	11.4%	4.6%	$45M	$241M	$193M
2019	$561M	$14M	16.6%	5.8%	7.4%	1.9%	$13M	$232M	$103M
2018	$520M	$11M	30.5%	17.0%	6.0%	2.1%	$24M	$0	$107M
2017	$356M	$26M	23.3%	9.9%	16.1%	5.3%	$50M	—	$100M
2017	—	-$9M	—	—	2534.7%	-43.4%	—	—	$63M
2016	—	$11M	—	—	13.1%	3.3%	$19M	—	$55M
2016	—	-$9M	—	—	736.1%	-47.8%	—	—	$9M
2015	—	-$2M	—	—	64.0%	-12.0%	—	$11M	$5M
2014	—	-$5M	—	—	191.7%	-126.8%	-$2M	—	$1M
2013	—	-$9M	—	—	2509.2%	-276.3%	$12157	—	$1M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
Jun '26	$973M	$20M	0.0%	3.5%	2.4%	0.9%	—	$936M	$401M
Mar '26	$965M	$14M	0.0%	3.0%	1.8%	0.6%	$64M	$1.0B	$478M
Dec '25	$951M	$6M	0.0%	1.9%	0.8%	0.3%	-$6M	$1.0B	$429M
Sep '25	$956M	$373000	0.0%	2.0%	0.0%	0.0%	$7M	$1.0B	$462M
Jun '25	$655M	$9M	0.0%	3.1%	1.2%	0.7%	$89M	$414M	$340M
Mar '25	$620M	$7M	0.0%	3.3%	0.9%	0.5%	$14M	$416M	$259M
Dec '24	$665M	-$7M	0.0%	0.1%	-1.0%	-0.5%	-$13M	$435M	$288M
Sep '24	$479M	$16M	0.0%	5.9%	2.3%	1.3%	$32M	$438M	$348M
Jun '24	$486M	$19M	0.0%	6.2%	2.8%	1.5%	$20M	$442M	$325M
Mar '24	$404M	$15M	0.0%	7.5%	2.3%	1.2%	$6M	$389M	$335M
Dec '23	$353M	$12M	0.0%	-1.1%	2.0%	1.3%	$12M	$278M	$294M
Sep '23	$348M	$22M	0.0%	11.2%	3.7%	2.1%	$11M	$209M	$274M
Jun '23	$348M	$13M	0.0%	7.8%	2.3%	1.3%	$14M	$208M	$294M
Mar '23	$337M	$13M	0.0%	6.6%	2.4%	1.3%	$2M	$206M	$275M
Dec '22	$294M	-$4M	0.0%	4.3%	-0.7%	-0.4%	$84M	$204M	$288M
Sep '22	$317M	$23M	0.0%	15.8%	4.6%	2.4%	-$39M	$202M	$184M
Jun '22	$270M	$12M	0.0%	5.7%	2.5%	1.2%	$8M	$201M	$234M
Mar '22	$263M	$14M	0.0%	10.0%	3.0%	1.5%	$7M	$185M	$238M
Dec '21	$195M	$12M	0.0%	1.2%	2.7%	1.4%	-$15M	$184M	$233M
Sep '21	$227M	$34M	0.0%	23.4%	7.9%	3.9%	$42M	$183M	$205M

Valuation over time

How the market has priced ASTH against its own fundamentals since 2024-02 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has risen from 43.3× (Feb '24) to 85.8× (Nov '26).
The price-to-sales ratio has fallen from 1.8× (Feb '24) to 0.6× (Nov '26).
The dividend yield has fallen from 2.5% (Feb '24) to 0.4% (Nov '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is ASTH growing its revenue and profit?

Over the past 5 years, Astrana Health, Inc.'s revenue has grown 35.9% per year, and net income declined 8.6% per year. These are computed facts, not advice.

How much debt does ASTH have?

As of FY2025, Astrana Health, Inc. reported $1.0B of total debt against $429M of cash; operating income covered interest expense 1.6×.

What is ASTH's profit margin?

In FY2025, gross margin was —, operating margin 2.5%, and net margin 0.8%.

What is ASTH's P/E ratio?

Astrana Health, Inc.'s P/E (TTM) is 50.79 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the ASTH stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 85.8× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.